Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth

British Journal of Cancer

Volumn 96, Issue 8, 2007, Pages 1204-1215

  Patel, J B ^a   Mehta, J ^a   Belosay, A ^a   Sabnis, G ^a   Khandelwal, A ^a   Brodie, A M H ^a,b   Soprano, D R ^c   Njar, V C O ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antitumour activity; Apoptosis; Breast cancer; Differentiation; RAMBAs; Retinoic acid

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLIN D1; CYTOKERATIN 18; CYTOKERATIN 8; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FENRETINIDE; LETROZOLE; PROTEIN BAD; PROTEIN BAX; RETINOIC ACID; RETINOIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VN 141; VN 501; VN 661; VN 691;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 9; CELL CYCLE; CELL PROLIFERATION; CYCLIN D1; FEMALE; FENRETINIDE; HUMANS; IMIDAZOLES; MICE; NEOPLASM TRANSPLANTATION; RECEPTORS, RETINOIC ACID; TRANSPLANTATION, HETEROLOGOUS; TRETINOIN;

EID: 34247368986     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603705     Document Type: Article

References (57)

1. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH (2004) Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 23: 8135-8145
2. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193
3. Arapshian A, Bertran S, Kuppumbatti YS, Nakajo S, Mira-y-lopez R (2004) Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogen-specific phenomenon in breast cancer. Mol Cancer 3: 13
4. Belosay A, Brodie AMH, Njar VCO (2006) Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole insensitive breast cancer cells. Cancer Res 66: 11485-11493
5. Bollag W, Isnardi L, Jablonska S, Klaus M, Majewski S, Pirson W, Toma S (1997) Links between pharmacological properties of retinoids and nuclear retinoid receptors. Int J Cancer 70: 470-472
6. Boyle JO (2001) Retinoids mechanisms and cyclins. Curr Oncol Rep 3: 301-305
7. Brodie AH, Jelovac D, Long B (2003) The intramural aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Molec Biol 86: 283-288
8. Budhu AS, Noy N (2002) Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Mol Cell Biol 22: 2632-2641
9. Chen LX, Zhang Z-P, Scafonas A, Cavalli RC, Gabriel JL, Soprano KJ, Soprano DR (1995) Arginine 132 of cellular retinoic acid-binding protein (Type II) is important for binding of retinoic acid. J Biol Chem 270: 4518-4525
10. Dragnev K, Rigas J, Dmitrovsky E (2000) The retinoids and cancer prevention mechanisms. Oncologist 5: 361-368
11. Fontana JA, Rishi AK (2002) Classical and novel retinoids: their targets in cancer therapy. Leukemia 16: 463-472
12. Gavrieli Y, Sherman Y, Ben-Sasson S (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501
13. Goss PE, Strasser K, Marques R, Clemons M, Oza A, Geol R, Blackstein M, Kaizer L, Sterns EE, Nabholtz JM, De Coster R, Crump M, Abdolell M, Qi S (2000) Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat 64: 177-188
14. Huynh CK, Brodie AMH, Njar VCO (2006) Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumor xenografts in SCID mice. Br J Cancer 94: 513-523
15. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AMH (2005) Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in postmenopausal breast cancer model. Cancer Res 65: 5439-5444
16. Jing Y, Zhang J, Waxman S, Mair-y-Lopez R (1996) Upregulation of cytokeratin 8 and 18 in human breast cancer T47D cells is retinoidspecific and retinoic acid receptor-dependent. Differentiation 60: 109-117
17. Kim J, Freeman MR (2003) JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79: 321-328
18. Korsching E, Packeisen J, Angelopoulos K, Eisenacher M, Voss R, Isola J, Van diest PJ, Brandt B, Boecker W, Buerger H (2002) Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82: 1525-1533
19. Kotake-Nara E, Kim SJ, Kobori M, Miyashita K, Nagao A (2002) Acycloretinoic acid induces apoptosis in human prostate cancer cells. Anticancer Res 22: 689-695
20. Kowalsski PJ, Rubin MA, Kleer GC (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: R217-R222
21. Lin F, Xiao D, Kolluri SK, Zhang X-K (2000) Unique anti-activator protein-1 activity of retinoic acid receptor β. Cancer Res 60: 3271-3280
22. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Brodie AM (2004) Therapeutic strategies using aromatase inhibitor letrozole and tamaxifen in breast cancer model. J Natl Cancer Inst 96: 456-465
23. Long BJ, Jelovac D, Thiantanawat A, Brodie AM (2002) The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8: 2378-2388
24. Marill J, Capron CC, Idres N, Chabot GG (2002) Human cytochrome P450s involved in the metabolism of 9-cis and 13-cis-retinoic acid. Biochem Pharmacol 63: 933-943
25. McSorley L, Daly A (2000) Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 60: 517-526
26. Mendoza-Gamboa E, Siwak DR, Tari AM (2004) The HER2/Grb2/Akt pathway regulates the DNA binding actiivty of AP-1 in breast cancer cells. Onco Rep 12: 903-908
27. Miller W (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83: 1471-1482
28. Moon RC, Mehta RG, McCormick DL (1985) Retinoids and mammary gland differentiation. Ciba Found Symp 113: 156-167
29. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB (1979) N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39: 1339-1346
30. Nass SJ, Herman JG, Gabrielison E, Iversen PW, Parl FF, Davidson NE, Graff JR (2000) Aberrant methylation of the estrogen receptor and E-cadherin 5′ Cpg islands increases with malignant progression in human cancer. Cancer Res 60: 4346-4348
31. Niu MY, Menard M, Reed JC, Krajewski S, Pratt MA (2001) Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells. Oncogene 20: 3506-3518
32. Njar VCO (2002) Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem 2: 261-269
33. Njar VCO, Gediya LK, Puurshottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J (2006a) Retinoic acid metabolism blocking agents (RAMBAs) for the treatment of cancers and dermatological diseases. Bioorg Med Chem 14: 4323-4340
34. Njar VCO, Gediya LK, Puurshottamachar P, Chopra P, Belosay A, Patel J (2006b) Retinoids in clinical use. Med Chem 2: 431-438
35. Njar VCO, Nnane IP, Brodie AMH (2000) Potent inhibition of retinoic acid metabolism enzymes by novel azolyl retinoids. Bioorg Med Chem Lett 10: 1905-1908
36. Njar VCO, Nnane IP, Brodie AMH (2005) Novel C-4 substituted retinoids. Australian Patent 2001271265: B2
37. Patel JB, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nanne IP, Soprano DR, Njar VCO (2004) Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem 47: 6716-6729
38. Pellegrini R, Mariotti A, Tagliabue E, Bressan R, Bunone G, Coradini D, Della Vella G, Formelli F, Cleris L, Radice P, Pierotti M, Colnaghi M, Menard S (1995) Modulation of markers associated with tumor aggressiveness in human breast cancer cell line by N-(4-hydroxyphenyl) retinamide. Cell growth Diff 6: 863-869
39. Scafonas A, Wolfgang CL, Gabriel JL, Soprano KJ, Soprano DR (1997) Differential role of homologous positively charged residues for ligand binding in retinoic acid receptor α compared with retinoic acid receptor β. J Biol Chem 272: 11244-11249
40. Schaller G, Buhler H (2005) Transfection of K18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 3: 365-371
41. Simeone AM, Tari AM (2004) How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 61: 1475-1484
42. Soprano DR, Scanlon E, Shukri M, Zhang Z-P, Soprano KJ (2000) Murine RARβ4 displays reduced transactivation activity, lower affinity for retinoic acid, and no anti-AP1 activity. J Cell Biochem 77: 604-614
43. 220. J Biol Chem 270: 18380-18387
44. Tanaka T, Dancheck BL, Trifiletti LC, Birnkrant RE, Taylor BJ, Garfield SH, Thorgeirsson U, De Luca LM (2004) Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231. Mol Cell Biol 24: 3972-3982
45. Teixeira C, Pratt MAC (1997) CDK2 is a target for retinoic acid mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endo 11: 1191-1202
46. Thiantanawat A, Long BJ, Brodie AM (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037-8050
47. Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R, Bollag W (1997) Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: growth inhibition and apoptosis induction. Int J Cancer 70: 619-627
48. Torrisi R, Decensi A (2000) Fenretinide and cancer prevention. Curr Oncol Rep 2: 263-270
49. Van Huesden J, Van Ginckel R, bruwiere H, Moelans P, janssen B, floren w, Leede BJ, Van Dun J, Sanz G, Venet M, Dillen L, Van Hove C, Willemsens G, Janicot M, Wouters W (2002) Inhibition of all-trans-retinoic acid metabolism by R116010 induces antitumor activity. Br J Cancer 86: 605-611
50. Wen Y, Yan DH, Spohn B, Deng J, Lin S-Y, Hung M-C (2000) Tumor suppression and sensitization to tumor necrosis factor α-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Res 60: 42-46
51. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K (2004) Downregulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 10: 2670-2674
52. Wouters W, Van Dun J, Dillen A, Coene M-C, Cools W, DeCoster R (1992) Effects of Liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 52: 2841-2846
53. Wu J, DiPietrantonio A, Hsieh T-C (2001) Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 6: 377-388
54. Yue W, Zhou D, Chen S, Brodie AMH (1994) A nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54: 5092-5095
55. Zhang Z-P, Hutcheson JM, Poynton HC, Gabriel JL, Soprano KJ, Soprano DR (2003) Arginine of retinoic acid receptor β which coordinates with the carboxyl group of retinoic acid functions independent of the amino acid residues responsible for retinoic acid receptor subtype ligand specificity. Arch Biochem Biophys 409: 375-384
56. Zhou Q, Stetler-Stevenson M, Steeg PS (1997) Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro. Oncogene 15: 107-115
57. Zou H, Li Y, Liu X, Wang X (1999) An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-11556